The Latest Breaking News from Eli Lilly

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.

The past week has been a rollercoaster ride for the financial markets. From President Donald Trump‘s surprising tariffs on gold to Eli Lilly’s worst day in 25 years, the week was filled with unexpected turns. Let’s dive into the top stories that shaped the week.

The U.S. stock market saw a mixed performance today, with the Nasdaq gaining over 70 points, reflecting a 0.35% increase to 21,242.70. Meanwhile, the SP 500 fell by 0.08% to 6,340, and the Dow Jones Industrial Average experienced a decline of 0.5% to settle at 43,968.64.

The S&P 500 Index ($SPX ) (SPY ) Thursday closed down -0.08%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.51%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.32%. September E-mini S&P futures (ESU25 ) fell -0.04%, and September E-mini Nasdaq futures (NQU25...

The main indexes finished well off their session highs after a disappointing batch of corporate earnings reports.

Results of study suggest orforglipron could be a simpler, cheaper alternative to injections

Eli Lilly Co. (NYSE:LLY) reported its second-quarter 2025 financial results ahead of the opening bell on Thursday.

U.S. equities slipped midday Thursday as corporate earnings and fresh tariff announcements from President Donald Trump drove divergent moves in heavyweight names.

Eli Lilly is poised for a major boost as new data shows its diabetes drug Mounjaro offers heart health benefits, potentially making it the top choice for patients with Type 2 diabetes.